FAQ
Log In
Saturday 10th December 2016
News
 › 
 › 

Topics referred to NICE in December 2012

28th January 2013

Ministers at the Department of Health have come to an agreement about the technology appraisal topics to refer to the National Institute of Health and Clinical Excellence (NICE).

NICE will handle the appraisals for the clinical and cost effectiveness of the following drugs (to treat a number of conditions including lung cancer and multiple sclerosis): afatinib, aflibercept, alemtuzumab, dimethyl fumarate, laquinimod, teriflunomide, dabrafenib, radium-223 dichloride, sipuleucel-T and ustekinumab. NICE is expected to respond to the referrals with guidance, which is usually produced within six months to two years.

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016